Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory forms of the disease. This innovative approach could revolutionize care, particularly in low-resource settings where traditional treatments are often out of reach. A recent comprehensive review explores the evolution, clinical applications, and prospects of MC, shedding light on its potential to improve outcomes while reducing toxicity.